Results 151 to 160 of about 193,906 (268)

Phosphoinositide 3-kinase inhibitors protect mouse kidney cells from cyclosporine-induced cell death.

Kidney International, 2008
E. Sarró, O. Tornavaca, M. Plana, A. Meseguer, E. Itarte   +4 more
semanticscholar   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Targeting the phosphoinositide 3-kinase pathway in cancer

Nature reviews. Drug discovery, 2009
Pixu Liu, Hailing Cheng, T. Roberts, Jean J. Zhao   +3 more
semanticscholar   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Development and Validation of a Urinary Exosomal miRNA Diagnostic Panel for Early Detection of Esophageal Cancer

Cancer Science, EarlyView.
Using a machine learning–based approach in a multi‐institutional prospective cohort, we identified a robust miRNA signature that demonstrated high diagnostic accuracy for esophageal squamous cell carcinoma. Our 57‐miRNA panel achieved an AUC of 0.90 in the proof‐of‐concept cohort and 0.85 in an independent validation cohort, with a sensitivity of 84 ...
Tatsuro Murano, Hiroki Yamashita, Yuki Kano, Ken Takeuchi, Takayuki Amano, Takanobu Yoshimoto, Mayuko Otomo, Hisashi Fujiwara, Shin Namiki, Hiroki Yamaguchi, Yoriko Ando, Yumi Nishiyama, Mika Mizunuma, Yuki Ichikawa, Tomonori Yano   +14 more
wiley   +1 more source

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. [PDF]

Oncogenesis, 2013
Huw LY, O'Brien C, Pandita A, Mohan S, Spoerke JM, Lu S, Wang Y, Hampton GM, Wilson TR, Lackner MR.   +9 more
europepmc   +1 more source

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Journal of Thoracic Oncology, 2011
V. Ludovini, F. Bianconi, L. Pistola, R. Chiari, V. Minotti, R. Colella, D. Giuffrida, F. Tofanetti, A. Siggillino, A. Flacco, E. Baldelli, D. Iacono, M. Mameli, A. Cavaliere, L. Crinò   +14 more
semanticscholar   +1 more source

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, EarlyView.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma. [PDF]

Cancer Drug Resist
Codenotti S, Marampon F, Megiorni F, Cattaneo CG, Gastaldello S, Pozzo E, Sampaolesi M, Rota R, Keller C, Fanzani A.   +9 more
europepmc   +1 more source